2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - Hall C
This is a strong session of new therapies for Myelofibrosis and 1 for Mast cell disease. If other clinical MPN session has 1 MF oral trial could move it here, and swap out the SM trial to theirs if makes sense.<br /><br />Sugested Title: <span style="caret-color: #000000; color: #000000; font-family: Aptos, Aptos_EmbeddedFont, Aptos_MSFontService, Calibri, Helvetica, sans-serif; font-size: 14.666667px; font-style: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration: none; display: inline !important; float: none;">MF and SM: Emerging Targets and Treatment Strategies</span>
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MPN, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence
PAPER

410 Avapritinib demonstrates rapid and durable symptom improvement, enhanced quality of life, and reductions in polypharmacy in patients with indolent systemic mastocytosis: Findings from the PIONEER study

Pankit Vachhani, MD, Cem Akin, MD, PhD2, Daniel J DeAngelo, MD, PhD3, Jason Gotlib4, Mariana C Castells, MD, PhD5, Sigurd Broesby-Olsen6, Tracy George, MD7, Karin Hartmann, MD8, Frank Siebenhaar, MD9, Ashley Doyle10, Teresa Green11, Janet Hong12, Ben Lampson, MD, PhD13, Hui-Min Lin14, Kate Newberry, PhD15, Tsewang Tashi, MD16
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 University of Michigan, Ann Arbor, Michigan, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Stanford Cancer Institute/Stanford University School of Medicine, Stanford, California, United States
5 Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States
6 Odense University Hospital, Odense, Denmark
7 ARUP Laboratories, University of Utah School of Medicine, Salt Lake City, Utah, United States, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
8 University Hospital Basel and University of Basel, Basel, Switzerland, University Hospital Basel and University of Basel, Basel, Switzerland, University Hospital Basel and University of Basel, Basel, Switzerland
9 Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany, Institute of Allergology, Charité–Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
10 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
11 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
12 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
13 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
14 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
15 Blueprint Medicines Corporation, Cambridge, Massachusetts, United States
16 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

Introduction:

Indolent systemic mastocytosis (ISM) is a clonal mast cell disease driven by the KIT D816V mutation in ~95% of cases and can cause chronic, debilitating symptoms and poor quality of life (QoL). Historically, management of ISM has centered on symptom-directed therapies that do not target the underlying disease biology, leaving many patients with ongoing symptom burden despite best supportive care (BSC) treatment. Avapritinib, an oral, potent, selective KIT D816V inhibitor, is approved for adults with ISM in the USA and for adults with moderate to severe ISM symptoms in the European Union. Here, we present the findings on symptom reduction, QoL improvements, and BSC reduction from the 4-year long-term follow-up of the PIONEER trial (NCT03731260).

Methods:

Adults with centrally confirmed ISM and moderate to severe symptoms who completed the randomized dose-finding (Part 1) or randomized, double-blind, placebo-controlled (Part 2) portions of PIONEER rolled over to the open-label, long-term extension (Part 3). This cumulative analysis includes patients who initiated avapritinib at the recommended dose of 25 mg once daily (QD) in either Parts 1, 2, or 3. Symptoms were assessed using the ISM-Symptom Assessment Form (ISM-SAF; ©2018 Blueprint Medicines Corporation). Long-term impact on QoL was assessed by patient-reported QoL measures: the Mastocytosis Quality-of-Life Questionnaire (MC-QoL), the EuroQoL five dimensions visual analogue scale (EQ-5D VAS), and the 12-Item Short Form Health Survey (SF-12), including the Physical Component Summary (PCS) and Mental Component Summary (MCS).

 

Results:

Overall, 226 patients initiated avapritinib 25 mg QD across Parts 1, 2, and 3. Median (range) treatment duration was 46.5 months (0.7–67.2) as of September 17, 2025.

Symptom improvement was sustained long-term with a mean change (standard deviation [SD]) from baseline in ISM-SAF total symptom score of –17.7 (19.3) at 1 year (n=193) and –17.7 (19.1) at 4 years (n=85). Seventy-eight percent (n=177/226) of patients achieved a ≥30% reduction in total symptom score with the median (range) time to reduction of 2.3 months (0.3–44.5).

Improvements in QoL measures were also durable through 4 years, with mean percent change (SD) from baseline in MC-QoL total scores of –31.0% (37.5) at 1 year (n=173) and –35.4% (35.7) at 4 years (n=79). Corresponding improvements from baseline in mean percent (SD) EQ-5D VAS scores were 22.6% (44.7) at 1 year (n=174) and 25.8% (47.1) through 4 years (n=80), consistent with clinically meaningful improvements based on published thresholds. SF-12 improvements were also maintained through 4 years (1 year, n=170; 4 years, n=78), with mean percent changes (SD) in SF-12 PCS scores of 19.9% (33.1) at 1 year and 20.5% (34.5) at 4 years, and corresponding improvements in SF-12 MCS scores of 11.1% (28.9) at 1 year and 10.5% (26.2) at 4 years, exceeding published thresholds for clinically meaningful change.

A progressive reduction in BSC usage was observed with long-term avapritinib treatment. At 1 year, 31% (n=69/226) of patients had reductions/discontinuations in one or more classes of BSC and at 3 years, 52% (n=118/226) of patients had reductions/discontinuations in one or more BSC classes. The largest percentage of patients with reductions or discontinuations of BSC usage at 3 years were observed for cromolyn sodium (36.5%, n=27/74), anti-immunoglobulin E therapy (34.5%, n=10/29), and H1 (31.2%, n=69/221) and H2 (28.8%, n=44/153) antihistamines.

Conclusion:

Avapritinib has demonstrated benefit in ISM across three distinct endpoints that are each uniquely important for management of this chronic disease: symptoms, QoL, and BSC use. Avapritinib rapidly and durably reduces disease-related symptoms which were maintained for at least 4 years. Avapritinib demonstrates sustained improvement in patient-reported QoL, as measured by validated tools such as MC-QoL, EQ-5D VAS, and SF-12. Furthermore, avapritinib facilitates reduction in the use of BSC medications, with more than half of participants having reduced or discontinued at least one class of BSC. Symptom and QoL improvements were maintained despite reductions in BSC, without exacerbating symptom burden. These findings demonstrate the breadth of benefit that patients with ISM receive from long-term avapritinib therapy.
Pankit Vachhani, MD: Alabama Cancer Congress - Honoraria; Amgen - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); CTI BioPharma Corp (now Sobi) - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); MorphoSys - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Consultancy (Includes expert testimony); Prelude Therapeutics - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Stemline - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)